Approval · Notice of Compliance 9823 · 2008
PREVACID: Notice of Compliance 9823
Issued October 9, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9823
- Date
- October 9, 2008
- Company
- Takeda Pharmaceuticals America IncCambridge, Massachusetts, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- H+, k+-atpase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREVACID | 02165503 | Marketed |
| PREVACID | 02165511 | Marketed |
| PREVACID | 02258609 | — |
| PREVACID | 02258617 | — |
| PREVACID FASTAB | 02249464 | Marketed |
| PREVACID FASTAB | 02249472 | Marketed |
| PREVACID I.V. | 02258080 | — |
Medicinal ingredients
- LANSOPRAZOLE 15 MG per CAP
- LANSOPRAZOLE 30 MG per CAP
- LANSOPRAZOLE 15 MG per DOSE
- LANSOPRAZOLE 30 MG per DOSE
- LANSOPRAZOLE 15 MG per TAB
- LANSOPRAZOLE 30 MG per TAB
- LANSOPRAZOLE SODIUM 30 MG per VIAL